Alexion Pharmaceuticals, Inc. today announced that the previously announced acquisition of Syntimmune has been successfully completed. The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor with Immunoglobulin G and IgG immune complexes with the potential to treat a number of rare IgG-mediated diseases.
“We’ve made significant progress rebuilding our pipeline this year, and the acquisition of Syntimmune is another critical step in continuing to expand and diversify our portfolio,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. “We’re very excited to continue the development of SYNT001, which we believe holds great promise in transforming patient care across a number of rare IgG-mediated diseases. We are rapidly advancing the current development programs and look forward to beginning two pivotal programs next year, including one in warm autoimmune hemolytic anemia.”
SYNT001 is currently being evaluated in Phase 1b/2a studies in patients with warm autoimmune hemolytic anemia and in patients with pemphigus vulgaris or pemphigus foliaceus and has demonstrated proof of mechanism showing rapid IgG reduction. Alexion plans to initiate two pivotal trials in 2019 – one in WAIHA, following successful completion of the current Phase 1b/2a study, and one in an undisclosed indication.
Date: November 5, 2018
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: MarketWatch
